Glycostem Therapeutics

Glycostem Therapeutics company information, Employees & Contact Information

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

Company Details

Employees
26
Founded
-
Address
Kloosterstraat 9, Oss,5349 Ab,netherlands
Phone
+31 (0) 412 211 001
Email
of****@****tem.com
Industry
Biotechnology
HQ
Oss
Looking for a particular Glycostem Therapeutics employee's phone or email?

Glycostem Therapeutics Questions

News

Natural killer cells making better cancer immunotherapies - Nature

Natural killer cells making better cancer immunotherapies Nature

Glycostem and medac sign deal on AML and MM product - Labiotech.eu

Glycostem and medac sign deal on AML and MM product Labiotech.eu

Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions - Frontiers

Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions Frontiers

Combinatorial Approach with Mass Spectrometry and Lectin Microarray Dissected Site-Specific Glycostem and Glycoleaf Features of the Virion-Derived Spike Protein of Ancestral and γ Variant SARS-CoV-2 Strains - ACS Publications

Combinatorial Approach with Mass Spectrometry and Lectin Microarray Dissected Site-Specific Glycostem and Glycoleaf Features of the Virion-Derived Spike Protein of Ancestral and γ Variant SARS-CoV-2 Strains ACS Publications

Off-the-shelf NK cells in hematologic malignancies and oncology - BioInformant

Off-the-shelf NK cells in hematologic malignancies and oncology BioInformant

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight GlobeNewswire

Glycostem’s oNKord Therapy for Myeloma Named FDA Orphan Drug - Rare Cancer News

Glycostem’s oNKord Therapy for Myeloma Named FDA Orphan Drug Rare Cancer News

Editorial: Translating NK cell scientific research to clinical product manufacturing - Frontiers

Editorial: Translating NK cell scientific research to clinical product manufacturing Frontiers

Natural killer cells: a thriving frontier in allogeneic cell therapy - Labiotech.eu

Natural killer cells: a thriving frontier in allogeneic cell therapy Labiotech.eu

Harnessing the power of natural killer cells for cancer immunotherapy - Nature

Harnessing the power of natural killer cells for cancer immunotherapy Nature

Glycostem launches pivotal oncology trial with evolved naked natural killer cells - Nature

Glycostem launches pivotal oncology trial with evolved naked natural killer cells Nature

Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90 - Frontiers

Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90 Frontiers

A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells - Nature

A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells Nature

Top Glycostem Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant